؉ channel (K ATP channel) activity in human pancreatic ␤-cells causes severe hypoglycemia in certain forms of hyperinsulinemic hypoglycemia, similar channel loss in sulfonylurea receptor-1 (SUR1) and Kir6.2 null mice yields a milder phenotype that is characterized by normoglycemia, unless the animals are stressed. While investigating potential compensatory mechanisms, we found that incretins, specifically glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic peptide (GIP), can increase the cAMP content of Sur1KO islets but do not potentiate glucose-stimulated insulin release. This impairment is secondary to a restriction in the ability of Sur1KO I nsulin secretion is a unique example of exocytosis controlled by metabolic, ionic, and hormonal pathways. An imbalance in insulin release due to disruption of these pathways can produce the profound changes in glucose homeostasis associated with either hyperglycemia (diabetes) or hypoglycemia (e.g., hyperinsulinemic hypoglycemia [HI]). In pancreatic ␤-cells, ATPsensitive K ϩ channels (K ATP channels), composed of Kir6.2 and the sulfonylurea receptor-1 (SUR1), and voltage-gated Ca 2ϩ channels are key players linking increased glucose metabolism to elevation of cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ). Membrane depolarization induced by closure of K ATP channels, secondary to changes in ADP/ ATP resulting from glucose metabolism, leads to the generation of Ca 2ϩ -dependent action potentials and [Ca 2ϩ ] i oscillations, which are considered to be a major mediator of insulin secretion. Sulfonylureas that block ␤-cell K ATP channels are commonly used to restore insulin secretion in type 2 diabetes. The loss or constitutive closure of ␤-cell K ATP channels, as a result of mutations in either subunit, is a cause of both dominant and recessive forms of HI (HI-SUR1 or HI-Kir6.2), characterized by elevated plasma insulin values inconsistent with the observed hypoglycemia (reviewed in 1,2). Studies on islets isolated from patients diagnosed with HI are consistent with hypersecretion of insulin (3,4). By comparison, the clinical phenotype of mice lacking ␤-cell/neuronal K ATP channels is strikingly normal. Kir6.2 null (Kir6.2KO) (5) and Sur1KO (6) mice are normoglycemic when fed, displaying only mild glucose intolerance, consistent with their loss of first phase and attenuated second phase of insulin release. Sur1KO mice exhibit greater hypoglycemia upon fasting, consistent with their inability to rapidly repolarize their ␤-cells and reduce insulin release (6). No compensating ionic mechanisms have been identified, and the electrophysiological phenotype of isolated K ATP KO mouse ␤-cells, i.e., constant membrane depolarization, presence of Ca 2ϩ -dependent action potentials, and elevated oscillating [Ca 2ϩ ] i in low glucose, is quite similar to that of ␤-cells from HI neonates (compare 5-7); therefore, it is unclear why K ATP KO islets lack the elevated basal insulin release observed in HI islets (3, 4) .
I
nsulin secretion is a unique example of exocytosis controlled by metabolic, ionic, and hormonal pathways. An imbalance in insulin release due to disruption of these pathways can produce the profound changes in glucose homeostasis associated with either hyperglycemia (diabetes) or hypoglycemia (e.g., hyperinsulinemic hypoglycemia [HI] ). In pancreatic ␤-cells, ATPsensitive K ϩ channels (K ATP channels), composed of Kir6.2 and the sulfonylurea receptor-1 (SUR1), and voltage-gated Ca 2ϩ channels are key players linking increased glucose metabolism to elevation of cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ). Membrane depolarization induced by closure of K ATP channels, secondary to changes in ADP/ ATP resulting from glucose metabolism, leads to the generation of Ca 2ϩ -dependent action potentials and [Ca 2ϩ ] i oscillations, which are considered to be a major mediator of insulin secretion. Sulfonylureas that block ␤-cell K ATP channels are commonly used to restore insulin secretion in type 2 diabetes. The loss or constitutive closure of ␤-cell K ATP channels, as a result of mutations in either subunit, is a cause of both dominant and recessive forms of HI (HI-SUR1 or HI-Kir6.2), characterized by elevated plasma insulin values inconsistent with the observed hypoglycemia (reviewed in 1,2). Studies on islets isolated from patients diagnosed with HI are consistent with hypersecretion of insulin (3, 4) . By comparison, the clinical phenotype of mice lacking ␤-cell/neuronal K ATP channels is strikingly normal. Kir6.2 null (Kir6.2KO) (5) and Sur1KO (6) mice are normoglycemic when fed, displaying only mild glucose intolerance, consistent with their loss of first phase and attenuated second phase of insulin release. Sur1KO mice exhibit greater hypoglycemia upon fasting, consistent with their inability to rapidly repolarize their ␤-cells and reduce insulin release (6) . No compensating ionic mechanisms have been identified, and the electrophysiological phenotype of isolated K ATP KO mouse ␤-cells, i.e., constant membrane depolarization, presence of Ca 2ϩ -dependent action potentials, and elevated oscillating [Ca 2ϩ ] i in low glucose, is quite similar to that of ␤-cells from HI neonates (compare 5-7); therefore, it is unclear why K ATP KO islets lack the elevated basal insulin release observed in HI islets (3, 4) .
In a search for differences in the regulation of insulin secretion, we discovered that the incretins (8) glucagonlike peptide-1 (GLP-1) and glucose-dependent insulino-tropic peptide (GIP) will increase cAMP content in both Sur1KO and wild-type islets. However, the increased cAMP potentiates glucose-induced insulin secretion only from wild-type islets, not from Sur1KO islets. We hypothesize that the impaired response of Sur1KO ␤-cells to elevated cAMP will reduce insulin secretion in response to incretins, and possibly other hormones, and thus provide one compensatory mechanism contributing to the normoglycemia of Sur1KO mice. Although the molecular nature of the defect remains to be described, we show that it does not impair the potentiation of insulin release by carbachol and phorbol esters and is upstream of the GTP-dependent step activated by mastoparan.
Glucose-induced insulin release from Sur1KO islets is not potentiated by incretins. Based on the estimated dissociation constant (K D ) for GLP-1 (ϳ200 pmol/l) (15) and plasma levels of GLP-1-(7-3)amide in mice after challenge with gastric glucose (ϳ15 pmol/l) (16), we used saturating concentrations (10 nmol/l) of GLP-1-(7-36) amide, GIP, and exendin-4, a GLP-1 receptor agonist (17) , to show that these peptides stimulate insulin secretion from wild-type but not Sur1KO islets ( Fig. 1A and B) . Stimulation of wild-type islets requires elevated glucose and is abolished by the L-type Ca 2ϩ channel blocker, nifedipine. The incretins comparably increase the steadystate islet cAMP content, indicating that the lack of response of Sur1KO islets is not due to altered coupling of incretin receptors with adenylyl cyclases (Fig. 1C) . One- way ANOVA indicated that there were no significant differences between the wild-type and Sur1KO values within a group or with glucose or nifedipine concentration; therefore, we averaged the wild-type and Sur1KO values within a group (Fig. 1D) . The potentiation of insulin release by cAMP is impaired in Sur1KO islets. To manipulate the cAMP content further, we inhibited phosphodiesterases with IBMX and stimulated adenylyl cyclases with forskolin. The intracellular content of cAMP ([cAMP] i ) is elevated similarly in both wild-type and Sur1KO islets after incubation (30 min) with forskolin, IBMX, or both agents ( Fig. 2A) . One-way ANOVA indicates there are no significant differences between the conditions within the four treatment groups, i.e., no treatment, plus IBMX, plus forskolin, or plus both agents; therefore, we averaged the values for the four islet groups. The grouped data are 86.79 Ϯ 33.02, 254.87 Ϯ 116.25, 2,471.9 Ϯ 948.87, and 10,905 Ϯ 3,167.3 fmol of cAMP/10 islets Ϯ SD for no treatment versus treatments with IBMX, forskolin, or IBMX plus forskolin, respectively. ANOVA on this grouped data indicates that the approximate threefold difference with and without the addition of IBMX does not reach statistical significance (P Ͼ 0.05), whereas the differences between the control (no treatment) and other treatments are highly significant (P Ͻ 0.001). Figure 2B shows the result of elevating [cAMP] i on glucose-dependent insulin release from wild-type versus Sur1KO islets. The data in Fig. 2A and B were obtained from the same islets and are replotted in Fig. 2C (18, 19) , superphysiologic concentrations of cAMP, Ͼ100-fold above basal values, significantly increased insulin release even in low glucose. Insulin release from Sur1KO islets in low glucose was about six times the basal rate of release or nearly twice as great as that obtained from wild-type islets in high glucose alone. In high glucose, Sur1KO islets exhibit a restricted stimulatory response at all [cAMP] i values relative to that observed from wild-type islets ( example. Fig. 3B protein kinase C (PKC) pathways by 500 nmol/l 12-Otetradecanoylphorbol 13-acetate (TPA) stimulates insulin release from both wild-type and Sur1KO islets. In high glucose, the rates of release from wild-type versus Sur1KO islets were indistinguishable (Fig. 4A) , suggesting saturation of the stimulatory effect. In low glucose, TPA significantly potentiates secretion from Sur1KO versus wild-type islets. Carbamylcholine (100 mol/l) potentiates insulin release from wild-type islets (Fig. 4B) ; stimulation is greatest in high glucose but is significant even in low glucose. Insulin secretion from Sur1KO islets is markedly stimulated by carbamylcholine in both low and high glucose (Fig. 4C) . Comparison of the release stimulated by glucose alone versus glucose plus carbamylcholine shows that there is a quantitatively greater effect on insulin release from Sur1KO islets, ϳ3.7 Ϯ 0.2-fold more than the control versus ϳ2.0 Ϯ 0.1-fold more for wild type, due mainly to the lower rate of secretion from the knockout islets. The results are consistent with the idea that the pathways by which PKC stimulates insulin secretion remain functional in Sur1KO islets. The potentiation of glucose-induced insulin release from wild-type islets is not sensitive to PKA inhibitors. It is not well understood where cAMP acts in the exocytotic pathway. Some have suggested that phosphorylation via PKA is critical for the action of cAMP in ␤-cells (29 -32) , but an early study (28) and recent reports indicate PKA-independent pathways are important in islets (33) (34) (35) (36) and in the regulation of other endocrine systems (37) . We tested whether inhibitors of PKA would block phosphorylation in wild-type islets and thus mimic the incretin refractory phenotype of Sur1KO islets. Three PKA inhibitors were used: H-89 (14) , the reportedly more specific KT5720 (38) , and (Rp)-Adenosine 3Ј,5Ј-monophosphorothioate (Rp-cAMPS) (39, 40) , which inhibits PKA and is resistant to phosphodiesterase but is expected to compete with cAMP for binding sites on Epac (exchange protein directly activated by cAMP)/cAMP-GEF (guaninenucleotide exchange factor) proteins (41, 42) without their activation (43) . Neither H-89 or KT5720 markedly altered the potentiating effect of GLP-1 (Fig. 5) at 5 mol/l, a concentration ϳ100-fold greater than the constants for inhibition (K i s) of PKA (48 and 60 nmol/l for H-89 [14] and KT5720 [38] ), respectively. Rp-cAMPS (100 mol/l; K i for PKA ϳ11 mol/l) did significantly inhibit potentiation of insulin release by elevated [cAMP] i , reducing secretion to ϳ30% of the control. Figure 6A and B summarize dose-response curves for H-89 and KT5720 on insulin release from wild-type islets. Neither H-89 (25 mol/l) nor KT5720 (25 mol/l) produced a statistically significant effect when all the data were analyzed by ANOVA. Preincubation with H-89 did not significantly affect the potentiation of glucose-induced insulin release by different concentrations of IBMX (Fig.  6C) ; the estimated half-maximal activation values for IBMX were 9.5 Ϯ 3.3 vs. 13.8 Ϯ 1.2 mol/l in the presence and absence of 5 mol/l H-89, respectively. Perifusion experiments (Fig. 6D) 
(25 mg/l)-permeabilized islets incubated with ␥[
32 P] ATP and a PKA substrate, Leu-Arg-Arg-Ala-Ser-Leu-Gly (12), were used to estimate PKA activity. The results show that both wild-type and Sur1KO islets have comparable levels of kinase activity, which is stimulated 8-to 10-fold by 5 mol/l cAMP, is inhibited by nanomolar concentrations of PKI (13) and by H-89 (Fig. 7A) .
To show that H-89 and KT5720 were able to inhibit PKA in intact islet preparations, we assessed their ability to block cAMP-stimulated phosphorylation of CREB in intact wild-type islets under the same conditions used to test their effect on insulin release. Although influenced by a variety of signals, including Ca 2ϩ , growth factors, and cellular stress (see 37,44 for reviews), phosphorylation of CREB is used as a reporter of cAMP-dependent kinase activity. H-89 (Fig. 7A) and KT5720 inhibited the increase in islet CREB phosphorylation observed when [cAMP] i was increased by IBMX treatment. The results are expressed as the ratio of phosphorylated CREB to total CREB, estimated using specific antibodies (Fig. 7C) . Basal phosphorylation of CREB due to the activity of other kinases is approximately one-third the level stimulated by addition of IBMX. H-89 and KT5720 (5 mol/l) completely blocked the stimulatory effect of IBMX on CREB phosphorylation consistent with their hydrophobic nature and estimated K D values in the nanomolar range (14, 38) . The results indicate that both compounds can enter islets and inhibit PKA(s) and confirm a report in insulinoma cells and rat islets (45) . The insulinotropic peptide mastoparan stimulates insulin release from Sur1KO islets. Mastoparan is a cationic, amphiphilic, 14 amino acid peptide that stimulates insulin release (46) reportedly at a late stage of exocytosis (47, 48) , an effect that is attenuated by pertussis toxin (46) , independent of increased [Ca 2ϩ ] i (47, 49) , augmented by nutrients, and dependent on GTP (48). Mastoparan prompts insulin release from Sur1KO islets in the absence of external Ca 2ϩ , and this effect is augmented by glucose, 3.5 Ϯ 0.8-fold for wild-type vs. 1.6 Ϯ 0.9-fold for Sur1KO islets (Fig. 8) 1.0, 3) 2.0 Ϯ 0.5 vs. 2.4 Ϯ 1.0, given as percentage of total insulin content ϮSD for wild-type versus Sur1KO islets, respectively. The augmentation by glucose appears to be abolished by prior treatment with mastoparan, because a third exposure to mastoparan in the absence of glucose gives an equivalent bolus of insulin to that obtained with 16.7 mmol/l glucose. The results suggest there is no general secretory defect in Sur1KO ␤-cells and are consistent with the idea that the cAMP-dependent step is upstream of the GTP-dependent Ca 2ϩ -independent step targeted by mastoparan (Fig. 8) .
DISCUSSION
We have shown that isolated islets from Sur1KO mice, lacking ␤-cell/neuronal-type K ATP channels, have an impaired insulin secretory response to cAMP. One physiologic consequence of this biochemical defect is that although the cAMP content of Sur1KO islets increases upon stimulation with incretins, the rate of insulin release is not affected, consistent with a defect in cAMP sensing. Our data suggest the cAMP response in wild-type islets is nonlinear; a small increase in [cAMP] i (Ͻ50% above basal values) is sufficient to increase insulin release two-to threefold when the glucose concentration is high. Blocking phosphodiesterase activity with IBMX elevates [cAMP] i about threefold above basal values, which is sufficient to saturate the potentiating effect of cAMP on glucose-induced insulin release from wild-type islets. Superphysiologic [cAMP] i , ϳ100-fold higher than basal levels, obtained with IBMX plus forskolin, has no stimulatory effect on insulin release from wild-type islets in low glucose, but does strongly potentiate insulin release from Sur1KO islets, which have elevated [Ca 2ϩ ] i , even in low glucose. The impaired response to incretins does not appear to result from a generalized defect in exocytosis, since insulin release is comparably stimulated from wildtype and Sur1KO islets by activators of PKC pathways and by mastoparan, which is reported to activate exocytosis at a late, GTP-dependent step (47, 48) .
What biochemical mechanisms are impaired when SUR1 is missing is not known. SUR1 is the regulatory subunit of SUR1/Kir6.2, ␤-cell/neuronal-type K ATP channels, but has not generally been considered to interact with other proteins or known to serve a function in exocytosis beyond modulating Ca 2ϩ entry via regulation of membrane potential. K ATP channels are reported to be inhibited by GLP-1 (50) . Various mechanisms have been put forward to account for this inhibition, including phosphorylation of SUR1/Kir6.2 subunits by PKA (although phosphorylation by PKA [51] or by PKC [52] is also reported to increase the open probability of K ATP channels), by direct binding of G-protein ␤␥ subunits to SUR1 (53) , by stimulation of glucose transport or metabolism (50) , and by increasing the sensitivity of K ATP channels to inhibitory ATP (54) . We think the simple explanation that loss of a potential GLP-1 target, i.e., K ATP channels, can account for the observed loss of incretin sensitivity is unlikely. If GLP-1 stimulates secretion by inhibiting K ATP channel activity, then insulin secretion from Sur1KO islets, a model system for constitutively closed K ATP channels, should exhibit sustained oversecretion equivalent to that stimulated by GLP-1, rather than the moderate, regulated secretion we observed.
How increased cAMP potentiates insulin secretion is not well understood. A number of reports have stressed the importance of PKA-dependent phosphorylation (29 -32) , but some early reports argued that basal and glucoseinduced insulin secretion are PKA independent (28, 55) . Exocytosis has been reported to be activated directly by cAMP (33, 56) , and two recent reports (34, 36) What contribution the impaired secretory response to cAMP of Sur1KO islets makes to the normoglycemia of the knockout mice versus the profound hypoglycemia of HI neonates lacking functional K ATP channels is not known. We considered several possibilities. First, that loss of the incretin response in Sur1KO islets disrupts the enteroinsular axis in the animals, reducing insulin secretion and glucose disposal, thus contributing to their normoglycemia. There is little insulin release after intraperitoneal injection of glucose into Kir6.2KO (5) and Sur1KO animals (6), and we anticipate that postprandial insulin levels in Sur1KO mice should be reduced versus wild type. However, although the data are controversial, GLP-1 has been reported to increase glucose uptake in peripheral tissues (compare 58,59 with 60 -62) and thus may contribute to glucose disposal in Sur1KO mice. We are not aware of any data on the incretin responsiveness of hyperinsulinemichypoglycemic neonates. A second possibility is that there is a basic difference in cAMP sensing in mouse versus human islets, as has been suggested to explain the difference in kinetics of second-phase secretion of mouse versus rat and human islets (63) . The available comparative data for knockout mouse versus HI islets are insufficient to address this question. Rates of insulin turnover have not been compared directly, but the insulin content of Sur1KO islets reported here is ϳ60% of wild-type values versus ϳ2.5% reported for HI islets (4), suggesting a higher turnover rate for the latter. Kaiser et al. (3) have also reported that cells derived from HI islets exhibit a high rate of glucose-independent insulin secretion, which is stimulated further by IBMX and forskolin. Similarly, Straub et al. (4) have shown that secretion from HI ␤-cells, determined by capacitance measurements, is potentiated by forskolin. However, in these studies, as in our experiments with IBMX and forskolin, [cAMP] i is increased to superphysiologic levels where insulin secretion is significantly increased in the Sur1KO islets, and it is difficult to extrapolate to a physiologic condition. Finally, it is important to consider that SUR1-regulated K ϩ channels are present in nonpancreatic tissues, where their loss could contribute to glycemic control, for example, through counterregulatory responses that may well differ between rodents and humans. 
